A Phase I Study of CG-806 in People with Recurrent or Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma


Full Title

A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkins Lymphomas


The purpose of this study is to find the highest dose of the investigational drug CG-806 that can be given in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or continued to grow despite prior treatment. CG-806 blocks two enzymes, BTK and FLT3, which play a role in cancer growth. Researchers think that by blocking these enzymes, CG-806 can stop cancer cells from growing and cause them to die. CG-806 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have CLL or SLL that has come back or continued to grow despite at least two prior regimens of therapy.
  • Patients may or may not have received another BTK inhibitor to treat their CLL or SLL.
  • At least 2 weeks must pass since the completion of prior therapy and receipt of CG-806.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Lindsey Roeker at 646-608-3748.





Disease Status

Relapsed or Refractory